Multicenter phase I/II study of switching therapy from lenalidomide and dexamethasone to elotuzumab plus lenalidomide and dexamethasone for multiple myeloma patients not achieving deep response
Not Applicable
Recruiting
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000032849
- Lead Sponsor
- orth Japan Hematology Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with HIV-antibody positive 2.Patients with synchronous or metachronous malignancy except carcinoma in situ or cancer confined to the mucosa and curatively treated by local resection 3.Patients with active infectious disease 4.Pregnant women, women who could be pregnant or women who is breast feeding 5.Patients with history of hypersensitivity for the component of elotuzumab 6.Patients with other inadequate conditions determined by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method